Work Package 3
Work Package 3 Clinical Imaging
Work Package 3 will provide a prototype matrix and infrastructure for rapid validation of imaging biomarkers to evaluate response to therapy. Imaging biomarkers for proliferation and apoptosis will be validated for use with currently available drug classes. This research matrix will set the stage in future for swift evaluation of new anticancer drug classes and regimens as well as informing on other biological aspects of drug action, applicable in a multicenter setting and in phase I/II therapeutic trials.
Participating QuIC-ConCePT partners:
- European Organisation for Research and Treatment of Cancer, AISBL, Belgium
- Universitair Ziekenhuis Antwerpen, Belgium
- The Institute of Cancer Research – Royal Marsden, United Kingdom
- VUmc Amsterdam, The Netherlands
- Manchester Cancer Research Centre, United Kingdom
- European Institute for Molecular Imaging at the Westfaelische Wilhelms-Universitaet Muenster, Germany
- Radboud University Nijmegen Medical Center, The Netherlands
- Imperial College London, United Kingdom
- AstraZeneca AB, Sweden
- Eli Lilly and Company Ltd, United Kingdom
- GlaxoSmithKline R&D Ltd, United Kingdom
- Merck KgAA, Germany
- Pfizer Limited, United Kingdom
- F. Hoffmann-La Roche AG, Switzerland
- Amgen NV, Belgium
QuIC-ConCePT